二氢嘧啶

Dihydropyrimidines are widely used as anti-cancer drugs, particularly in the treatment of colorectal cancer.
二氢叶酸还原酶抑制剂在抗癌药物中被广泛应用，特别是在治疗结直肠癌方面。
The mechanism of action of 5-fluorouracil (5-FU), a common dihydropyrimidine, involves its conversion to a form that interferes with DNA replication.
常见的二氢叶酸衍生物5-氟尿嘧啶（5-FU）的作用机制是转化为一种干扰DNA复制的形式。
Dihydropyrimidines are often administered in combination with other chemotherapy agents to enhance their therapeutic effects.
二氢叶酸还原酶抑制剂常常与其他化疗药物联合使用以增强其治疗效果。
A side effect of long-term dihydropyrimidine therapy is an increased risk of bone marrow suppression.
长期使用二氢叶酸还原酶抑制剂的一个副作用是增加骨髓抑制的风险。
Dihydropyrimidines are known to have a significant impact on the immune system, which can be both beneficial and detrimental depending on the patient's condition.
二氢叶酸还原酶抑制剂对免疫系统有显著影响，这取决于患者的具体状况，可能是有益的也可能是有害的。
In vitro studies have shown that dihydropyrimidines inhibit the growth of various cancer cell lines by interfering with thymidylate synthesis.
体外研究显示，二氢叶酸还原酶抑制剂通过干扰胸苷酸合成抑制多种癌细胞系的生长。
The pharmacokinetics of dihydropyrimidines can vary greatly among individuals, affecting drug efficacy and potential toxicity.
不同个体间二氢叶酸还原酶抑制剂的药代动力学有很大差异，这会影响药物疗效和潜在毒性。
Some patients undergoing dihydropyrimidine therapy experience nausea and vomiting, which can be managed with anti-emetic medications.
部分接受二氢叶酸还原酶抑制剂治疗的患者会出现恶心和呕吐，可通过抗恶心药物进行管理。
The development of resistance to dihydropyrimidines is a concern in cancer treatment, necessitating the use of combination therapies.
对抗二氢叶酸还原酶抑制剂产生耐药性是癌症治疗中的一个顾虑，需要采用联合疗法。
Researchers are continually exploring novel modifications to dihydropyrimidines to overcome resistance and improve treatment outcomes for cancer patients.
研究人员正在不断探索对二氢叶酸还原酶抑制剂进行创新改造，以克服耐药性并提高癌症患者的治疗效果。